JP2013543896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543896A5 JP2013543896A5 JP2013541010A JP2013541010A JP2013543896A5 JP 2013543896 A5 JP2013543896 A5 JP 2013543896A5 JP 2013541010 A JP2013541010 A JP 2013541010A JP 2013541010 A JP2013541010 A JP 2013541010A JP 2013543896 A5 JP2013543896 A5 JP 2013543896A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- methyl
- lupus erythematosus
- systemic lupus
- dimethylcyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41668910P | 2010-11-23 | 2010-11-23 | |
| US61/416,689 | 2010-11-23 | ||
| PCT/US2011/061769 WO2012071374A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007618A Division JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的ｂｃｌ−２阻害薬を用いた処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543896A JP2013543896A (ja) | 2013-12-09 |
| JP2013543896A5 true JP2013543896A5 (enExample) | 2015-01-15 |
| JP5876067B2 JP5876067B2 (ja) | 2016-03-02 |
Family
ID=45218888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541010A Expired - Fee Related JP5876067B2 (ja) | 2010-11-23 | 2011-11-22 | 選択的ｂｃｌ−２阻害薬を用いた処置方法 |
| JP2016007618A Expired - Fee Related JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的ｂｃｌ−２阻害薬を用いた処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016007618A Expired - Fee Related JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的ｂｃｌ−２阻害薬を用いた処置方法 |
Country Status (36)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| SG190399A1 (en) | 2010-11-23 | 2013-06-28 | Abbvie Inc | Methods of treatment using selective bcl-2 inhibitors |
| CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
| WO2013090645A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| CN104768581A (zh) | 2012-09-07 | 2015-07-08 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
| EP3293185A1 (en) | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| EP3139942B1 (en) * | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2016205334A1 (en) | 2015-06-16 | 2016-12-22 | Vascular Strategies Llc | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| PE20181088A1 (es) | 2015-08-10 | 2018-07-09 | Dana Farber Cancer Inst Inc | Mecanismo de resistencia a inhibidores de bromodominio bet |
| BR112018008882A8 (pt) | 2015-11-03 | 2019-02-26 | Univ Texas | método para tratar um distúrbio proliferativo e produto farmacêutico |
| JP6936498B2 (ja) * | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| CN110483501B (zh) * | 2016-08-05 | 2022-07-01 | 密歇根大学董事会 | 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 |
| WO2019001383A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
| US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
| CA3087262A1 (en) | 2018-01-10 | 2019-07-18 | Recurium Ip Holdings, Llc | Benzamide compounds |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| US20190328729A1 (en) | 2018-04-26 | 2019-10-31 | Emory University | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto |
| CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772640B (zh) | 2018-07-31 | 2023-02-03 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与利妥昔单抗和/或苯达莫司汀或与CHOP联合的协同抗肿瘤作用 |
| WO2020061216A1 (en) | 2018-09-18 | 2020-03-26 | Signalchem Lifesciences Corporation | Combination therapy for treating blood cancer |
| MX2021004856A (es) | 2018-10-29 | 2021-10-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2. |
| US12319689B2 (en) | 2019-05-24 | 2025-06-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
| EP4139359A1 (en) | 2020-04-24 | 2023-03-01 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| CN115397825B (zh) | 2020-04-29 | 2025-09-09 | 正大天晴药业集团股份有限公司 | 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体 |
| EP4199924A4 (en) * | 2020-08-21 | 2024-08-28 | Ascentage Pharma (Suzhou) Co., Ltd. | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS |
| AU2022240765A1 (en) * | 2021-03-19 | 2023-09-07 | Eil Therapeutics, Inc. | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
| US20250319183A1 (en) * | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| WO2022253313A1 (zh) | 2021-06-04 | 2022-12-08 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类化合物的磷酸酯 |
| IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
| WO2024102890A2 (en) * | 2022-11-11 | 2024-05-16 | The Board Of Regents Of The University Of Texas System | Amino acid-benzoic acid oligomers and methods of use thereof for treating cancer |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| EP1019385B1 (en) | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxides |
| DE122004000004I1 (de) | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| ATE416772T1 (de) | 1998-07-06 | 2008-12-15 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| US6492389B1 (en) * | 1998-07-21 | 2002-12-10 | Thomas Jefferson University | Small molecule inhibitors of BCL-2 proteins |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| NZ519380A (en) | 1999-12-28 | 2004-10-29 | Eisai Co Ltd | Heterocyclic compounds having sulfonamide groups |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| ATE335722T1 (de) | 2001-06-06 | 2006-09-15 | Lilly Co Eli | Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| US20090247613A1 (en) | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1480650B1 (en) | 2002-02-26 | 2010-04-28 | AstraZeneca AB | Novel crystalline forms of the anti-cancer compound zd1839 |
| MY135609A (en) | 2002-02-26 | 2008-05-30 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| EP1737850B1 (en) | 2004-04-19 | 2007-10-03 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| US7429661B2 (en) | 2004-07-20 | 2008-09-30 | Symed Labs Limited | Intermediates for linezolid and related compounds |
| JP5128948B2 (ja) | 2004-08-27 | 2013-01-23 | ニッポネックス インコーポレイテッド | 癌の治療のための新規な薬剤組成物 |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| AU2006247322A1 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| PL2395004T3 (pl) | 2005-06-22 | 2016-08-31 | Plexxikon Inc | Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| AU2006320162B2 (en) | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
| KR20100012031A (ko) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| CN101842362A (zh) * | 2007-09-27 | 2010-09-22 | 沃尔特及伊莱萨霍尔医学研究院 | 苯并噻唑化合物 |
| CN101809090A (zh) | 2007-10-01 | 2010-08-18 | 阿科玛股份有限公司 | 可生物降解的聚合物以及丙烯酸共聚物的共混物 |
| JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| CA2703724C (en) * | 2007-10-19 | 2017-07-11 | Burnham Institute Of Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| NZ601350A (en) | 2007-11-16 | 2013-08-30 | Abbvie Inc | Method of treating arthritis |
| MX2010006260A (es) | 2007-12-06 | 2010-08-23 | Abbott Lab | Composiciones orales de abt-263 para tratar cancer. |
| CN101481363B (zh) * | 2008-01-10 | 2011-05-04 | 江苏豪森药业股份有限公司 | 一种制备瑞格列奈的方法 |
| NZ600979A (en) | 2008-01-15 | 2014-01-31 | Abbott Lab | Improved mammalian expression vectors and uses thereof |
| WO2009129317A1 (en) * | 2008-04-15 | 2009-10-22 | Burnham Institute For Medical Research | An inhibitor of anti-apoptotic proteins |
| ES2598178T5 (es) | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| NZ592801A (en) * | 2008-12-05 | 2013-08-30 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US20110245156A1 (en) | 2008-12-09 | 2011-10-06 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| HUE025527T2 (en) | 2009-01-19 | 2016-04-28 | Abbvie Inc | Apoptosis inducers for the treatment of cancer, immune and autoimmune diseases |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102448959B (zh) | 2009-05-26 | 2015-06-17 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| TWI471321B (zh) | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
| SG190399A1 (en) * | 2010-11-23 | 2013-06-28 | Abbvie Inc | Methods of treatment using selective bcl-2 inhibitors |
-
2011
- 2011-11-22 SG SG2013040167A patent/SG190399A1/en unknown
- 2011-11-22 ES ES11793928.0T patent/ES2603129T3/es active Active
- 2011-11-22 UY UY0001033746A patent/UY33746A/es not_active Application Discontinuation
- 2011-11-22 DK DK11793928.0T patent/DK2642999T3/en active
- 2011-11-22 MX MX2013005849A patent/MX346201B/es active IP Right Grant
- 2011-11-22 AU AU2011332000A patent/AU2011332000B2/en not_active Ceased
- 2011-11-22 BR BR112013012854-2A patent/BR112013012854B1/pt not_active IP Right Cessation
- 2011-11-22 RU RU2013128544/14A patent/RU2593231C2/ru active
- 2011-11-22 UA UAA201307893A patent/UA113157C2/uk unknown
- 2011-11-22 EP EP16153335.1A patent/EP3028702B1/en active Active
- 2011-11-22 EP EP11793928.0A patent/EP2642999B1/en active Active
- 2011-11-22 KR KR1020197027331A patent/KR20190109590A/ko not_active Withdrawn
- 2011-11-22 KR KR1020187007228A patent/KR20180030257A/ko not_active Ceased
- 2011-11-22 HU HUE11793928A patent/HUE031267T2/en unknown
- 2011-11-22 PT PT117939280T patent/PT2642999T/pt unknown
- 2011-11-22 TW TW100142779A patent/TWI535701B/zh not_active IP Right Cessation
- 2011-11-22 SG SG10201509631SA patent/SG10201509631SA/en unknown
- 2011-11-22 MY MYPI2013700925A patent/MY165884A/en unknown
- 2011-11-22 ES ES16153335T patent/ES2701603T3/es active Active
- 2011-11-22 MX MX2017000835A patent/MX377232B/es unknown
- 2011-11-22 LT LTEP11793928.0T patent/LT2642999T/lt unknown
- 2011-11-22 PH PH1/2013/501006A patent/PH12013501006A1/en unknown
- 2011-11-22 PL PL11793928T patent/PL2642999T3/pl unknown
- 2011-11-22 JP JP2013541010A patent/JP5876067B2/ja not_active Expired - Fee Related
- 2011-11-22 HR HRP20161762TT patent/HRP20161762T1/hr unknown
- 2011-11-22 UA UAA201607110A patent/UA119150C2/uk unknown
- 2011-11-22 CN CN201180065747.XA patent/CN103402521B/zh not_active Expired - Fee Related
- 2011-11-22 WO PCT/US2011/061769 patent/WO2012071374A1/en not_active Ceased
- 2011-11-22 RS RS20161159A patent/RS55545B1/sr unknown
- 2011-11-22 CA CA2820618A patent/CA2820618C/en not_active Expired - Fee Related
- 2011-11-22 MY MYPI2017000882A patent/MY191300A/en unknown
- 2011-11-22 KR KR1020137016217A patent/KR101841084B1/ko not_active Expired - Fee Related
- 2011-11-22 TW TW105100832A patent/TWI620736B/zh not_active IP Right Cessation
- 2011-11-22 AR ARP110104338A patent/AR083946A1/es unknown
- 2011-11-22 US US13/301,898 patent/US20120129853A1/en not_active Abandoned
- 2011-11-22 SI SI201131050A patent/SI2642999T1/sl unknown
- 2011-11-22 NZ NZ610746A patent/NZ610746A/en not_active IP Right Cessation
- 2011-11-22 NZ NZ708508A patent/NZ708508A/en not_active IP Right Cessation
- 2011-11-22 CN CN201610007260.0A patent/CN105664164B/zh not_active Expired - Fee Related
-
2013
- 2013-05-16 ZA ZA2013/03589A patent/ZA201303589B/en unknown
- 2013-05-21 IL IL226490A patent/IL226490A/en active IP Right Grant
- 2013-05-22 CL CL2013001458A patent/CL2013001458A1/es unknown
- 2013-05-22 GT GT201300136A patent/GT201300136A/es unknown
- 2013-06-07 CR CR20130268A patent/CR20130268A/es unknown
- 2013-06-21 EC ECSP13012710 patent/ECSP13012710A/es unknown
-
2014
- 2014-11-06 US US14/535,070 patent/US9345702B2/en active Active
-
2016
- 2016-01-19 JP JP2016007618A patent/JP6215368B2/ja not_active Expired - Fee Related
- 2016-04-22 US US15/136,582 patent/US9872861B2/en active Active
- 2016-05-20 PH PH12016500939A patent/PH12016500939B1/en unknown
- 2016-06-27 AU AU2016204396A patent/AU2016204396B2/en not_active Ceased
- 2016-12-13 CY CY20161101289T patent/CY1118442T1/el unknown
-
2017
- 2017-03-03 DO DO2017000056A patent/DOP2017000056A/es unknown
- 2017-04-20 IL IL251845A patent/IL251845B/en active IP Right Grant
- 2017-12-12 US US15/838,605 patent/US20180369250A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,515 patent/US20200222413A1/en not_active Abandoned